Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August
June 29, 2023 08:00 ET
|
Cingulate Inc.
KANSAS CITY, Kan., June 29, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest
June 14, 2023 15:45 ET
|
Cingulate Inc.
KANSAS CITY, Kan., June 14, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD
June 08, 2023 07:00 ET
|
Cingulate Inc.
Study Assessed Onset and Duration of CTx-1301 in Adults, Results Expected 3Q 2023 Pivotal Phase 3 Trials in Pediatric/Adolescent Patients on Schedule for 3Q 2023 Initiation KANSAS CITY, Kan., June ...
ChildCare Education Institute Offers No-Cost Online Course on Attention Deficit Hyperactivity Disorder
June 01, 2023 00:58 ET
|
ChildCare Education Institute
ATLANTA, GA, June 01, 2023 (GLOBE NEWSWIRE) -- ChildCare Education Institute® (CCEI), one of the largest online training providers dedicated exclusively to the early care and education workforce,...
Cingulate to Present at 13th Annual LD Micro Invitational
May 25, 2023 15:55 ET
|
Cingulate Inc.
KANSAS CITY, Kan., May 25, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate, Indegene to Participate in Benzinga All Live Access Event
May 12, 2023 15:45 ET
|
Cingulate Inc.
KANSAS CITY, Kan., May 12, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update
May 10, 2023 16:15 ET
|
Cingulate Inc.
Additional $3 Million of Financing Proprietary PTR™ Manufacturing Processes Successfully Transferred to Societal CDMO Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301 KANSAS...
Cingulate Announces Successful Transfer of CTx-1301 (dexmethylphenidate) Proprietary PTR™ Manufacturing Processes to Societal CDMO
May 03, 2023 06:45 ET
|
Cingulate Inc.
KANSAS CITY, Kan., May 03, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
ADHD Therapeutics Market Size Worth USD 19740 Million by 2030 at 7.80% CAGR – Report by Market Research Future (MRFR)
May 01, 2023 09:00 ET
|
Market Research Future
New York, USA, May 01, 2023 (GLOBE NEWSWIRE) -- ADHD Therapeutics Market Overview According to a Comprehensive Research Report by Market Research Future (MRFR), ADHD Therapeutics...
MHA releases analysis of its online mental health screens taken in 2022; 6.3M global screenings taken, nearly 500k took new ADHD screen
May 01, 2023 06:30 ET
|
Mental Health America
Alexandria, VA, May 01, 2023 (GLOBE NEWSWIRE) -- More than 6.3 million people worldwide in 2022 took a mental health screening using the Mental Health America (MHA) Online Screening Program, a...